(Massachusetts, USA) – Rubix LS, a pioneer in patient-centered clinical research and AI-driven real-world data analysis, and TheraSyn Bio (TSB), a Massachusetts-based synthetic biology enterprise specializing in precision bioscience and next-generation therapeutic development, have announced a joint venture for Project Panacea, a groundbreaking initiative to develop a topical breast cancer therapy*.
This collaboration combines Rubix LS’s deep expertise in breast cancer data and patient insights with TSB’s bioengineering platform to explore a localized, precision-based treatment designed to improve therapeutic efficacy while reducing systemic toxicity.
Project Panacea: A Joint Effort to Drive Early-Stage Development
Project Panacea is in its early stages, with a primary focus on conducting preclinical research to evaluate the safety, efficacy, and feasibility of a novel topical therapy for breast cancer. By integrating real-world patient data insights with bioengineered therapeutics, the joint venture seeks to redefine how localized therapies are developed and improve precision-based treatment strategies.
Bridging AI-Driven Data Insights with Synthetic Biology
Traditional breast cancer treatments rely on systemic therapies, which, while effective, can cause significant side effects due to broad drug exposure. Project Panacea is designed to overcome these limitations by combining Rubix LS’s disease modeling and patient stratification expertise with TSB’s bioengineered therapeutic development capabilities to create a targeted, localized solution.
Key anticipated benefits of Project Panacea include:
Enhanced Targeted Therapy – Ensuring localized delivery to optimize therapeutic impact.
Minimized Systemic Exposure – Reducing adverse effects associated with conventional treatments.
Expanded Accessibility – Offering a non-invasive, patient-friendly alternative, particularly for underserved communities.
Preclinical Development: Establishing a Foundation for Future Innovation
The initial phase of Project Panacea will focus on preclinical studies to assess the feasibility, stability, and penetration efficacy of the topical therapy. The research will provide key data to refine formulation development and support future regulatory engagement. Upon successful validation, Rubix LS and TSB will explore clinical development pathways to advance the therapy toward broader patient access.
This is a joint venture specifically for Project Panacea and does not indicate a corporate merger.
Statement from Rubix LS
Rubix LS is a research catalyst organization specializing in patient-centered clinical research, real-world evidence analysis, and AI-driven insights. The company focuses on bridging data and innovation to drive more equitable and effective health outcomes, with an emphasis on underserved patient populations.
“We are excited about the potential impact of Project Panacea,” said Reginald Swift, CEO of Rubix LS. “By harnessing our real-world patient data, we can refine disease models and optimize therapeutic design, accelerating the path to a more personalized and effective treatment solution.”
Statement from TheraSyn Bio
TheraSyn Bio is a precision bioscience biotechnology company focused on next-generation therapeutics using cutting-edge synthetic biology to accelerate tissue repair and healing. The company’s proprietary platform enables the rapid engineering of bioactive compounds, fostering innovative treatment modalities aligned with patient-specific needs. TheraSyn Bio has established partnerships with leading universities.
“TSB is excited about this collaboration with Rubix LS, which is built on a shared commitment to accelerating the development of patient-focused solutions,” said Daisy Gallagher, Co-Founder of TSB.
Media Contact:
Rubix LS Media Team